logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10472392 B1

PDFFull Text
Date of Patent:
Nov. 12, 2019

Filed:

Feb. 02, 2017

Macrocyclic inhibitors of flaviviridae viruses

Applicants:

Cypralis Limited, Cambridge, GB;

Gilead Sciences, Inc., Foster City, CA (US);

Inventors:

Caroline Aciro, Bottisham, GB;

Jean Yves Chiva, Essex, GB;

David Kenneth Dean, Ware, GB;

Adrian John Highton, Chelmsford, GB;

Petr Jansa, San Mateo, CA (US);

Andrew John Keats, Essex, GB;

Linos Lazarides, London, GB;

Richard Mackman, Millbrae, CA (US);

Karine G. Poullennec, Essex, GB;

Adam James Schrier, Redwood City, CA (US);

Dustin Scott Siegel, San Carlos, CA (US);

Victoria Alexandra Steadman, Essex, GB;

Greg Watt, Bristol, GB;

Assignees:

Gilead Sciences, Inc., Foster City, CA (US);

Cypralis Limited, Cambridge, GB;

Attorney:

Sheppard Mullin Richter & Hampton LLP

Primary Examiner:

Kaipeen E Yang

Int. Cl.
CPC ...
C07K 5/02 (2006.01); A61K 38/12 (2006.01); A61K 39/29 (2006.01); A61K 38/15 (2006.01); C07D 487/08 (2006.01); C07D 498/08 (2006.01); C07D 498/18 (2006.01); C07D 498/22 (2006.01); A61K 45/06 (2006.01); A61K 39/05 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 5/0202 (2013.01); A61K 38/12 (2013.01); A61K 39/05 (2013.01); A61K 39/29 (2013.01); A61K 45/06 (2013.01); C07D 487/08 (2013.01); C07D 498/08 (2013.01); C07D 498/18 (2013.01); C07D 498/22 (2013.01); C07K 5/02 (2013.01); A61K 38/00 (2013.01); A61K 38/15 (2013.01); Y02A 50/385 (2018.01); Y02A 50/387 (2018.01); Y02A 50/389 (2018.01); Y02A 50/391 (2018.01); Y02A 50/393 (2018.01); Y02A 50/395 (2018.01);
Abstract

Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.

Find Patent Forward Citations

Loading…